Report cover image

Global Axial Spondyloarthritis Medications Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 116 Pages
SKU # APRC20340173

Description

Summary

According to APO Research, The global Axial Spondyloarthritis Medications market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Axial Spondyloarthritis Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Axial Spondyloarthritis Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Axial Spondyloarthritis Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Axial Spondyloarthritis Medications include Abbott, Johnson & Johnson, Novartis, Pfizer, Bayer, Verywell, UCB, Sun Pharmaceutical Industries and Reddy Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Axial Spondyloarthritis Medications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Axial Spondyloarthritis Medications.

The Axial Spondyloarthritis Medications market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Axial Spondyloarthritis Medications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Axial Spondyloarthritis Medications Segment by Company

Abbott
Johnson & Johnson
Novartis
Pfizer
Bayer
Verywell
UCB
Sun Pharmaceutical Industries
Reddy Pharmaceuticals
Perrigo Company
Novacap
Merck Sharp & Dohme
Kopran
GlaxoSmithKline
Geri-Care Pharmaceuticals
Eli Lilly and Co.
DICE Therapeutics
Cigna
AstraZeneca
Axial Spondyloarthritis Medications Segment by Type

Injection
Oral
Axial Spondyloarthritis Medications Segment by Application

Hospital
Clinic
Other
Axial Spondyloarthritis Medications Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Axial Spondyloarthritis Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Axial Spondyloarthritis Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Axial Spondyloarthritis Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Axial Spondyloarthritis Medications manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Axial Spondyloarthritis Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

116 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Axial Spondyloarthritis Medications Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Axial Spondyloarthritis Medications Sales Estimates and Forecasts (2020-2031)
1.3 Axial Spondyloarthritis Medications Market by Type
1.3.1 Injection
1.3.2 Oral
1.4 Global Axial Spondyloarthritis Medications Market Size by Type
1.4.1 Global Axial Spondyloarthritis Medications Market Size Overview by Type (2020-2031)
1.4.2 Global Axial Spondyloarthritis Medications Historic Market Size Review by Type (2020-2025)
1.4.3 Global Axial Spondyloarthritis Medications Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Axial Spondyloarthritis Medications Sales Breakdown by Type (2020-2025)
1.5.2 Europe Axial Spondyloarthritis Medications Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Axial Spondyloarthritis Medications Sales Breakdown by Type (2020-2025)
1.5.4 South America Axial Spondyloarthritis Medications Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Axial Spondyloarthritis Medications Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Axial Spondyloarthritis Medications Industry Trends
2.2 Axial Spondyloarthritis Medications Industry Drivers
2.3 Axial Spondyloarthritis Medications Industry Opportunities and Challenges
2.4 Axial Spondyloarthritis Medications Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Axial Spondyloarthritis Medications Revenue (2020-2025)
3.2 Global Top Players by Axial Spondyloarthritis Medications Sales (2020-2025)
3.3 Global Top Players by Axial Spondyloarthritis Medications Price (2020-2025)
3.4 Global Axial Spondyloarthritis Medications Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Axial Spondyloarthritis Medications Major Company Production Sites & Headquarters
3.6 Global Axial Spondyloarthritis Medications Company, Product Type & Application
3.7 Global Axial Spondyloarthritis Medications Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Axial Spondyloarthritis Medications Market CR5 and HHI
3.8.2 Global Top 5 and 10 Axial Spondyloarthritis Medications Players Market Share by Revenue in 2024
3.8.3 2023 Axial Spondyloarthritis Medications Tier 1, Tier 2, and Tier 3
4 Axial Spondyloarthritis Medications Regional Status and Outlook
4.1 Global Axial Spondyloarthritis Medications Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Axial Spondyloarthritis Medications Historic Market Size by Region
4.2.1 Global Axial Spondyloarthritis Medications Sales in Volume by Region (2020-2025)
4.2.2 Global Axial Spondyloarthritis Medications Sales in Value by Region (2020-2025)
4.2.3 Global Axial Spondyloarthritis Medications Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Axial Spondyloarthritis Medications Forecasted Market Size by Region
4.3.1 Global Axial Spondyloarthritis Medications Sales in Volume by Region (2026-2031)
4.3.2 Global Axial Spondyloarthritis Medications Sales in Value by Region (2026-2031)
4.3.3 Global Axial Spondyloarthritis Medications Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Axial Spondyloarthritis Medications by Application
5.1 Axial Spondyloarthritis Medications Market by Application
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Other
5.2 Global Axial Spondyloarthritis Medications Market Size by Application
5.2.1 Global Axial Spondyloarthritis Medications Market Size Overview by Application (2020-2031)
5.2.2 Global Axial Spondyloarthritis Medications Historic Market Size Review by Application (2020-2025)
5.2.3 Global Axial Spondyloarthritis Medications Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Axial Spondyloarthritis Medications Sales Breakdown by Application (2020-2025)
5.3.2 Europe Axial Spondyloarthritis Medications Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Axial Spondyloarthritis Medications Sales Breakdown by Application (2020-2025)
5.3.4 South America Axial Spondyloarthritis Medications Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Axial Spondyloarthritis Medications Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Abbott
6.1.1 Abbott Comapny Information
6.1.2 Abbott Business Overview
6.1.3 Abbott Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Abbott Axial Spondyloarthritis Medications Product Portfolio
6.1.5 Abbott Recent Developments
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Comapny Information
6.2.2 Johnson & Johnson Business Overview
6.2.3 Johnson & Johnson Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Johnson & Johnson Axial Spondyloarthritis Medications Product Portfolio
6.2.5 Johnson & Johnson Recent Developments
6.3 Novartis
6.3.1 Novartis Comapny Information
6.3.2 Novartis Business Overview
6.3.3 Novartis Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis Axial Spondyloarthritis Medications Product Portfolio
6.3.5 Novartis Recent Developments
6.4 Pfizer
6.4.1 Pfizer Comapny Information
6.4.2 Pfizer Business Overview
6.4.3 Pfizer Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer Axial Spondyloarthritis Medications Product Portfolio
6.4.5 Pfizer Recent Developments
6.5 Bayer
6.5.1 Bayer Comapny Information
6.5.2 Bayer Business Overview
6.5.3 Bayer Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bayer Axial Spondyloarthritis Medications Product Portfolio
6.5.5 Bayer Recent Developments
6.6 Verywell
6.6.1 Verywell Comapny Information
6.6.2 Verywell Business Overview
6.6.3 Verywell Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Verywell Axial Spondyloarthritis Medications Product Portfolio
6.6.5 Verywell Recent Developments
6.7 UCB
6.7.1 UCB Comapny Information
6.7.2 UCB Business Overview
6.7.3 UCB Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.7.4 UCB Axial Spondyloarthritis Medications Product Portfolio
6.7.5 UCB Recent Developments
6.8 Sun Pharmaceutical Industries
6.8.1 Sun Pharmaceutical Industries Comapny Information
6.8.2 Sun Pharmaceutical Industries Business Overview
6.8.3 Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Product Portfolio
6.8.5 Sun Pharmaceutical Industries Recent Developments
6.9 Reddy Pharmaceuticals
6.9.1 Reddy Pharmaceuticals Comapny Information
6.9.2 Reddy Pharmaceuticals Business Overview
6.9.3 Reddy Pharmaceuticals Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Reddy Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio
6.9.5 Reddy Pharmaceuticals Recent Developments
6.10 Perrigo Company
6.10.1 Perrigo Company Comapny Information
6.10.2 Perrigo Company Business Overview
6.10.3 Perrigo Company Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Perrigo Company Axial Spondyloarthritis Medications Product Portfolio
6.10.5 Perrigo Company Recent Developments
6.11 Novacap
6.11.1 Novacap Comapny Information
6.11.2 Novacap Business Overview
6.11.3 Novacap Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Novacap Axial Spondyloarthritis Medications Product Portfolio
6.11.5 Novacap Recent Developments
6.12 Merck Sharp & Dohme
6.12.1 Merck Sharp & Dohme Comapny Information
6.12.2 Merck Sharp & Dohme Business Overview
6.12.3 Merck Sharp & Dohme Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Merck Sharp & Dohme Axial Spondyloarthritis Medications Product Portfolio
6.12.5 Merck Sharp & Dohme Recent Developments
6.13 Kopran
6.13.1 Kopran Comapny Information
6.13.2 Kopran Business Overview
6.13.3 Kopran Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Kopran Axial Spondyloarthritis Medications Product Portfolio
6.13.5 Kopran Recent Developments
6.14 GlaxoSmithKline
6.14.1 GlaxoSmithKline Comapny Information
6.14.2 GlaxoSmithKline Business Overview
6.14.3 GlaxoSmithKline Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.14.4 GlaxoSmithKline Axial Spondyloarthritis Medications Product Portfolio
6.14.5 GlaxoSmithKline Recent Developments
6.15 Geri-Care Pharmaceuticals
6.15.1 Geri-Care Pharmaceuticals Comapny Information
6.15.2 Geri-Care Pharmaceuticals Business Overview
6.15.3 Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio
6.15.5 Geri-Care Pharmaceuticals Recent Developments
6.16 Eli Lilly and Co.
6.16.1 Eli Lilly and Co. Comapny Information
6.16.2 Eli Lilly and Co. Business Overview
6.16.3 Eli Lilly and Co. Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Eli Lilly and Co. Axial Spondyloarthritis Medications Product Portfolio
6.16.5 Eli Lilly and Co. Recent Developments
6.17 DICE Therapeutics
6.17.1 DICE Therapeutics Comapny Information
6.17.2 DICE Therapeutics Business Overview
6.17.3 DICE Therapeutics Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.17.4 DICE Therapeutics Axial Spondyloarthritis Medications Product Portfolio
6.17.5 DICE Therapeutics Recent Developments
6.18 Cigna
6.18.1 Cigna Comapny Information
6.18.2 Cigna Business Overview
6.18.3 Cigna Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Cigna Axial Spondyloarthritis Medications Product Portfolio
6.18.5 Cigna Recent Developments
6.19 AstraZeneca
6.19.1 AstraZeneca Comapny Information
6.19.2 AstraZeneca Business Overview
6.19.3 AstraZeneca Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2020-2025)
6.19.4 AstraZeneca Axial Spondyloarthritis Medications Product Portfolio
6.19.5 AstraZeneca Recent Developments
7 North America by Country
7.1 North America Axial Spondyloarthritis Medications Sales by Country
7.1.1 North America Axial Spondyloarthritis Medications Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Axial Spondyloarthritis Medications Sales by Country (2020-2025)
7.1.3 North America Axial Spondyloarthritis Medications Sales Forecast by Country (2026-2031)
7.2 North America Axial Spondyloarthritis Medications Market Size by Country
7.2.1 North America Axial Spondyloarthritis Medications Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Axial Spondyloarthritis Medications Market Size by Country (2020-2025)
7.2.3 North America Axial Spondyloarthritis Medications Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Axial Spondyloarthritis Medications Sales by Country
8.1.1 Europe Axial Spondyloarthritis Medications Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Axial Spondyloarthritis Medications Sales by Country (2020-2025)
8.1.3 Europe Axial Spondyloarthritis Medications Sales Forecast by Country (2026-2031)
8.2 Europe Axial Spondyloarthritis Medications Market Size by Country
8.2.1 Europe Axial Spondyloarthritis Medications Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Axial Spondyloarthritis Medications Market Size by Country (2020-2025)
8.2.3 Europe Axial Spondyloarthritis Medications Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Axial Spondyloarthritis Medications Sales by Country
9.1.1 Asia-Pacific Axial Spondyloarthritis Medications Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Axial Spondyloarthritis Medications Sales by Country (2020-2025)
9.1.3 Asia-Pacific Axial Spondyloarthritis Medications Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Axial Spondyloarthritis Medications Market Size by Country
9.2.1 Asia-Pacific Axial Spondyloarthritis Medications Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Axial Spondyloarthritis Medications Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Axial Spondyloarthritis Medications Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Axial Spondyloarthritis Medications Sales by Country
10.1.1 South America Axial Spondyloarthritis Medications Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Axial Spondyloarthritis Medications Sales by Country (2020-2025)
10.1.3 South America Axial Spondyloarthritis Medications Sales Forecast by Country (2026-2031)
10.2 South America Axial Spondyloarthritis Medications Market Size by Country
10.2.1 South America Axial Spondyloarthritis Medications Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Axial Spondyloarthritis Medications Market Size by Country (2020-2025)
10.2.3 South America Axial Spondyloarthritis Medications Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Axial Spondyloarthritis Medications Sales by Country
11.1.1 Middle East and Africa Axial Spondyloarthritis Medications Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Axial Spondyloarthritis Medications Sales by Country (2020-2025)
11.1.3 Middle East and Africa Axial Spondyloarthritis Medications Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Axial Spondyloarthritis Medications Market Size by Country
11.2.1 Middle East and Africa Axial Spondyloarthritis Medications Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Axial Spondyloarthritis Medications Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Axial Spondyloarthritis Medications Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Axial Spondyloarthritis Medications Value Chain Analysis
12.1.1 Axial Spondyloarthritis Medications Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Axial Spondyloarthritis Medications Production Mode & Process
12.2 Axial Spondyloarthritis Medications Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Axial Spondyloarthritis Medications Distributors
12.2.3 Axial Spondyloarthritis Medications Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.